Here are the 10-K annual reports from Nexentis Technologies Inc. (NXTS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow NXTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NXTS filings page.
Nexentis Technologies, Inc. files its annual report outlining a major strategic shift into oncology drug discovery and renewable energy projects. The company completed the acquisition of MitoCareX Bio Ltd. in October 2025, making it a wholly owned subsidiary focused on mitochondrial-targeted therapies for cancers such as non-small cell lung and pancreatic cancer, using its proprietary MITOLINE™ computational platform.
Nexentis also expanded into European solar and battery storage through a February 2025 agreement to purchase 70% of SB Storage 1 S.R.L. alongside Solterra Renewable Energy. It exited its legacy post-harvest food business by transferring approximately 98% of Save Foods Ltd. to Voice Assist, Inc. in March 2026. As of June 30, 2025, non‑affiliate equity had a market value of $6,387,364, and as of March 31, 2026, 5,111,362 common shares were outstanding. The company, together with MitoCareX, operates with seven full-time and two part-time employees.